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Abstract  
In December 2019, there was a health emergency worldwide named novel coronavirus or COVID-19 by 
the world health organization (WHO). It originated from the Wuhan seafood market, Hubei Province, 
China. Till now Severe Acute Respiratory Syndrome Coronavirus-2 or SARS-CoV-2 spread over 216 
countries with 177,108,695 confirmed cases and 3,840,223 confirmed death cases has been reported 
(5:31 pm CEST, 18 June 2021; WHO). Analyzing the risk factor of this pandemic situation, different 
government health organizations of all the countries including WHO are taking several preventive 
measures with ongoing research works, even the vaccination process started. In this study, we tried to 
analyze all the available information on pandemic COVID-19, which includes the origin of COVID-19, 
pathogenic mechanism, transmission, diagnosis, treatment, and control-preventive measures, also the 
additional treatment and prevention taken by the Indian government is being studied here. 
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1. Introduction 
In December 2019, World Health Organization 
(WHO) was reported unknown symptoms of 
pneumonia cases by the Chinese Health Authority in 
Wuhan City in Hubei Province, China. It was reported 
that most of the patients with positive cases were 
connected to the Wuhan seafood wholesale market [1]. 
WHO named it the novel coronavirus or 2019-nCoV 
on 7th January 2020 [2]. It was identified from the 
swab test sample of patients. Later, the coronavirus 
Study Group and WHO renamed it as severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) 
[3]. On 30th January 2020, China reported 79,394 
confirmed cases and 12,167 suspected cases; more 
than 82 confirmed cases were reported from eighteen 
other countries [4]. On the same day, WHO declared it 
as a worldwide pandemic emergency [5]. Initially, 
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National Health Commission (China) reported to 
WHO that inside of China the mortality rate was 2.1%, 
whereas the outside of China was reported with a 0.2% 
mortality rate (4th Feb 2020) [6]. Among the admitted 
patients, the mortality rate was between 11%-15% [7]. 
Coronavirus disease 2019 (COVID-19) was reported as 
a highly infectious disease with a higher spreading rate 
than the mortality rate [8]. This study aimed to analyze 
the available information of pandemic COVID-19 
including pathogenic mechanism, transmission, 
diagnosis, treatment, and control-preventive 
measures. 
 
1.1 Origin and cataloging of COVID-19 
The analysis of the genome sequence of SARS-
CoV-2 reveals the whole genome sequence recognition 
rates of bat SARS coronavirus (SARSr-CoV-RaTG13) 
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was 96% whereas SARS-CoV was 79.5% [9]. This 
shows that COVID-19 might have their origination 
from bats. Gradually the rate of active cases is 
increasing [10]. SARS-CoV-2 is a family member of 
Coronaviridae and the order Nidovirales. The family is 
subdivided into Torovirinae and Coronaviridae, 
furthermore, Coronaviridae is divided into four 
categories: (I) α-coronavirus consists of human 
coronavirus (HCoV-229E and HCoV-NL63); (II) β-
coronavirus consists of SARS-HCoV (Severe Acute 
Respiratory Syndrome), HCoV-OC43, MERS-CoV 
(Middle-Eastern Respiratory Syndrome 
Coronavirus); (III) γ-coronavirus consists of the 
viruses for birds and whales; (IV) δ-coronavirus [11]. 
SARS-CoV-2 originated from β-coronavirus 
combined with two highly pathogenic viruses Middle-
Eastern respiratory syndrome coronavirus (MERS-
CoV) and severe acute respiratory syndrome (SARS-
HCoV), respectively [12]. The phylogenetic analysis of 
novel coronavirus or SARS-CoV-2 shows that the 
connection of the virus is linked with two different 
viruses (88% related) which derive from the bat, bat-
SL-CoVZXC21, and bat-SL-CoVZC45, respectively 
which genetically differs from MERS-CoV and SARS-
CoV [13]. Further research work with the help of 
genome sequences of RaTG13, SARS-CoV, and SARS-
CoV-2 shows that the virus is associated with Bat CoV 
RaTG13 which was previously found in Rhinolophus-
affinis from Wuhan Province (overall 96%  genome 
sequence) [14]. No evidence of recombination was 
found in the genome of a novel coronavirus from other 
viruses which originated from bats liked Bat CoV 
RaTG13, SARS-CoV. Further studies suggest that the 
origin of this virus is from the bat family [13]. 
Although, a related study is going on if there was any 
mediator via which the virus was transmitted to 
human bodies. Reasons which shows that bats are not 
solely responsible for the human transmission of 
coronavirus are as follows: (i) availability of several 
non-aquatic animals which also consists of mammals 
for selling in Wuhan seafood market but there was no 
sign of bats; (ii) novel coronavirus and its neighbors 
bat-SL-CoVZXC21 and bat-SL-CoVZC45 which have a 
comparatively long branch (less than 90% sequence 
identity), recommends that those viruses have no 
direct connection with SARS-CoV-2; (iii) other 
animals (civets, most probably camels respectively) 
acted as a mediator where the bat is the host in the 
coronavirus cases like MERS-CoV and  SARS-CoV 
[14]. Basically, coronavirus consists of single-stranded 
RNA viruses with a diameter of 80–120 nm. It can be 
categorized into four types- (i) α-coronavirus; (ii) β-
coronavirus; (iii) γ- coronavirus; and (iv) δ-
coronavirus [15]. Figure 1 shows the various types of 
coronavirus. Other than SARS-CoV-2, more than six 
coronaviruses including MERS-CoV and SARS-CoV 
have been identified before. The homology of SARS-
CoV and SARS-CoV-2 in the genome sequence is 
roughly 79%; which is similar to SARS-like bat 
coronavirus (MG772933) [16, 17]. 
 
1.2 COVID-19 pathogenic mechanism  
Several studies show that novel coronavirus uses 
the ACE2 which is known as the “Angiotension 
Converting Enzyme-2” receptor, which is similar to 
SARS-CoV  [18]. This virus mostly knows it’s 
consistent that targets the upper layer of the cells by 
the by S proteins (Figure 2a); which results in 
infection. A study indicates that novel coronavirus 
fixes to ACE2 with more than ten folds higher 
similarity than SARS-CoV, the stage beyond the 
inception needed for virus contagion [19]. The 
complete process through which COVID-19 affects 
humans by fixing spike protein to ACE2 shows in 
Figure 2b, the strong point of the contact for the threat 
of human transmission, and how this virus causes 
organ failure is still unknown. These outcomes 
describe the quicker transmission ability of novel 
coronavirus in humans as related to SARS-CoV, and 
 
 
Figure 1. Various categories of coronavirus 
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the most number of confirmed cases of SARS-CoV-2 
as associated with the infection of SARS-CoV. Since 
the most similarity of novel coronavirus fixes to ACE2, 
this receptor can be a possible applicant for the cure of 
novel coronavirus [20]. 
 
1.3 Transmission of SARS-CoV-2 
The spreading of coronavirus or SARS-CoV-2 by 
the Wuhan seafood market is still not clear. Initially, it 
was said that the novel corona virus-positive incidents 
were associated with this marketplace (animal to 
human transmission) [21]. Genomic research has 
delivered such evidence which shows the virus was 
originated from an unidentified place in the market, 
where it has spread nearer, however it was noticed that 
the transmission from human to human has 
happened previously [22]. The human-to-human 
transmission has been confirmed by the infected 
family members and health workers [23]. It was 
reported after 1st January that only 10% of the positive 
cases were related to the Wuhan seafood market and 
more than 70% of the patients were not related to that 
market [21]. It was predicted that human transmission 
happens in close contact especially through 
respiratory droplets originate from an infected 
persons’ sneezes and coughs. It was found that SARS-
CoV and other coronaviruses can stay on the surfaces 
for up to 96 hrs and 9 days, respectively [24, 25].  
On 30th January 2020, an asymptomatic 
transmission was reported [26], but by the 
researchers, no direct interview of the patient was 
reported, who had symptoms of transmission of 
disease [27]. An asymptomatic transmission was 
reported on 21st February 2020 [28]. The mean 
incubation period was reported to be 5.2 (95% CI: 4.1–
7.0) days [16]. This period can be elongated to 19 or 24 
days [29, 30], however, the case descriptions usually 
depend on a fourteen days window [31]. Also, 
reproductive number (R0) is predicted with 
fluctuating outcomes and analyses. It also measures 
the typical number of infected cases which results in 
one infected case to the whole population [32]. Figure 
3 shows the transmission of coronavirus. Previous 
studies found reproductive number (R0) is to be 2.7 
and 2.4 for SARS [33], and 2009 pandemic H1N1 
influenza [34]. Another study predicted that the 
reproductive number (95% CI: 1.4–3.9) was 2.2 [13]. 
Although, further studies suggested the reproductive 
number (R0) to be 3.28 [35]. Normally reproductive 
number (R0) represents the typical value which is 
considered to be the sole transmitter, which is most 
responsible for the spreading of epidemics in large 
groups [36]. In a severe case like epidemic or 
pandemic, reproductive number (R0) is unstable [32]. 
There is a risk of transmission if a pregnant woman is 
admitted to the hospital but no such maternal and fetal 
casualty, and vertical utero-transmission were noticed 
[37]. Currently, 177,108,695 confirmed cases and 
3,840,223 confirmed death cases have been reported 
[5:31 pm CEST, 18 June 2021; WHO] (Supplementary 
Figure 1). The confirmed cases of the individual 
countries affected by COVID-19 are given in 






Figure 2. A. Genome structure of SARS-CoV-2; B. SARS-CoV-2 infects the host cell 
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1.4 The epidemiology of novel coronavirus 
On 3rd March 2020, a total of 87,317 positive 
cases has been confirmed by WHO. Among all the 
definite cases, about 2,977 cases have yielded to the 
virus. The common symptoms and demises are 
informed by China. From the entire figure of positive 
cases, 79,968 infected patients have been recognized 
in China [38]. The common symptoms and demises 
are informed by China. From the entire figure of 
positive cases, 79,968 infected patients have been 
recognized in China [39]. It has been found that the 
clinical characteristics of 1,099 numbers of COVID- 19 
patients, where the median incubation period time 
was approximately 3 days, basically the range is 0–24 
days, the average period from the development of the 
symptoms to death was approximately 14 days [40]. 
For SARS-CoV septicity, the median expectancy was 
four days, the typical intermission from indication 
beginning to the taken to hospital was three days, and 
the usual interim from hospital entry time to death was 
seventeen days [41]. The median expectancy of the 
infection of MERS-CoV was seven days. The average 
development period for novel coronavirus is smaller 
than that for MERS and SARS, respectively. 
Conversely, the maximum expectancy of novel 
coronavirus currently detected is as high as twenty-
four days, which may raise the threat of virus 
transmission. Furthermore, persons aged more than 
seventy years had a shorter medium interval 
approximately eleven days from the indication start to 
death associated with patients aged less than seventy 
years, signifying that infection progress is speedier in 
aged persons related with elder persons [38, 42]. 
 
1.5 Risk factors of COVID-19 
The cases of SARS-CoV-2 septicity are realized 
most frequently in mature man patients with the 
middle age of the peoples was between thirty-four and 
fifty-nine years old [43, 44]. The novel coronavirus is 
also more likely to contaminate people with lifelong 
diseases like cerebrovascular and diabetes diseases, 
respectively [45]. The maximum amount of severe 
problems happens in mature ages more than sixty 
years, and with assured essential circumstances, for 
example, diabetes, cerebrovascular and cardiovascular 
diseases, respectively [46]. Severe appearances may be 
also connected with infected bacteria and fungi 
respectively. Also, below 15 years of age lower number 
of COVID-19 cases are reported [47]. Figure 4 shows 
the effect of coronavirus on the human body. A recent 
study published on Jan 29th stated that among 425 
patients of COVID-19 cases in Wuhan, China no cases 
were reported below 15 years of age [48]. The medical 
features of the pediatric infected patients were 
different, and the majority of patients had mild 
symptoms, having no low-grade fever and or 
pneumonia along with a good prognosis.  Another 
report stated that though a kid had ground-glass 
radiological lung denseness, while the patient showed 
no symptoms [49]. From this, the conclusion that can 
be made is that children are less likely to get an 
infection than adults. Also, if infection occurs in 
children mild manifestations are shown than adults 
which can lead to no treatment of their parents 
because of underestimate COVID-19 symptoms in 
that age range. 
 
 
Figure 3. Transmission routes of coronavirus 
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1.6 Clinical features 
Novel coronavirus generates an acute viral 
infection in patients with a middle incubation period 
of 3 days [48]; which is related to SARS, with two to 
ten days of incubation period [49]. The main signs of 
novel coronavirus are cough, fever, fatigue, and 
diarrhea, respectively [50], like other coronavirus 
symptoms. Many positive patients had an appearance 
of some degree of dyspnea; the intermission from 
indication start to the appearance of severe respiratory 
distress syndrome which was only nine days within the 
initial cases [51]. Moreover, severe cases are prone to a 
variety of complications, including secondary 
infection, and acute respiratory distress syndrome 
[52]. Based on the report in Wuhan's first 425 detected 
cases, the mutual indications contain fever, dry cough, 
myalgia, and fatigue with fewer normal are headache, 
hemoptysis, sputum production, diarrhea, and 
abdominal [21]. Nearly 75% of patients had bilateral 
pneumonia [53]. Unalike from MERS-CoV and SARS-
CoV symptoms, SARS-CoV-2 less likely indicate 
projecting upper respiratory tract marks and sore 
throat, sneezing, signifying that the virus might have a 
better tendency for contaminating the lower 
respiratory tract [54]. It is reported that pregnant 
women may have fewer COVID-19 symptoms than 
non-pregnant women but should take intensive care if 
severely infected [55]. Some reports also state that 
novel coronavirus can be harmful to organs and 
tissues other than the lungs. Another study states that 
out of 214 positive patients 78 patients had 
neurological symptoms [56]. Additionally, there is 
evidence SARS-CoV-2 RNA was detected in eye 
secretions of patients [57]. Computerized tomography 
(CT) scan is an essential tool to identify this 
pneumonia. Numerous usual imaging topographies 
are normally detected in novel coronavirus 
pneumonia, as well as 50% of leading ground-glass 
consolidations, 65% of opacity, 35% of a plane or 
unequal interlobular septal thickening, 47% of lower 
lobe involvement air bronchograms, predominantly 
peripheral and 32% of condensing of the adjacent 
pleura [58]. A current study described that 90% of 
patients had bilateral chest CT scan report results, and 
the understanding of chest CT scan report to suggest 
97% of novel coronavirus [59]. Merging CT scan 
reports with clinical indication and laboratory results 
could allow initialing medicare treatment of 
pneumonia of novel coronavirus. 
1.7 Diagnosis 
The WHO endorses gathering samples from lower 
as well as upper respiratory tracts. This can be attained 
by endotracheal aspirate, expectorated sputum, and 
bronchoalveolar lavage [59]. These models are then 
evaluated for viral RNA by polymerase chain reaction 
(PCR). When a positive result comes retest on the 
 
 
Figure 4. Effects of COVID-19 on human 
 
 
Figure 5. Different diagnoses process of COVID-19 
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sample should be done and if negative comes a retest 
is also done for confirmation. The recognition of viral 
nucleic acid is normal for the non-invasive analysis of 
the novel COVID-19. Figure 5 shows the various 
diagnosis process of COVID-19.  
 
1.8 Treatment  
Currently like the previous coronaviruses SARS-
CoV and MERS-CoV there is no specific treatment for 
COVID-19. Supportive care like fluid management, 
oxygen therapy, antibiotic treatment of the bacterial 
secondary infection, and isolation are suggested [60]. 
Few cases of COVID-19 patients advance quickly to 
septic shock and acute respiratory distress syndrome 
(ARDS) which leads to multiple organ failure [61]. So 
it is very much important to stop the spread of the 
disease by infection control measures and isolating the 
patient and providing necessary treatments for 
recovering from the disease [62]. Currently, COVID-19 
patient treatments are commonly symptomatic. For 
this kind of RNA coronaviruses Remdesivir an 
antiviral drug showed positive results in most cases.  In 
a report, Holshue et al. stated that Remdesivir shower 
good results on many patients of COVID-19 [63]. A 
drug for treating malaria, Chloroquine has been found 
to show the activity of immune-modulatory and has 
shown an antiviral effect on SARS-CoV-2 in vitro. In 
the clinic also it is seen that the drug Chloroquine 
showed positive results [64]. Currently, the drug 
Remdesivir is also being used on the COVID-19 
patients till now the drug efficacy is unknown [65]. 
Influenza viruses fusion were been blocked by a 
molecule Umifenovir (trade name Arbido) which is a 
small indole-derivative molecule. Recently it has been 
suggested that Umifenovir can help fight against 
COVID-19 [66]. If sepsis is recognized, antibiotics of 
empiric type should be directed depending on clinical 
diagnosis and susceptibility information, and local 
epidemiology. Daily glucocorticoid direction is not 
suggested if there are additional signs [67]. Usage of 
intravenous immunoglobulin could be helpful for 
extremely ill patients. Drug evaluation in line with past 
inquiries into the treatments for therapeutic in MERS 
and SARS [68]. Though there is no proof that these 
drugs can improve the patient's condition clinically. 
An empirical antibiotic treatment combined with 
antiviral drug Oseltamivir was employed for treating 
COVID-19 cases [71]. In the USA Ebola antiviral drug, 
Remdesivir is employed for the treatment of COVID-
19 patients. For 3 to 4 infected COVID-19 patients 
combination of drugs like Shufeng Jiedu Capsule 
(SFJDC), Lopinavir/Ritonavir a traditional Chinese 
medicine, Arbidol showed promising results [65, 69-
71]. Various other antiviral drugs are also being 
proposed for the treatment of COVID-19. Also, a few 
medicines are recommended for the treatment of 
COVID-19, which are given in Table 1 [70-72]. 
 
1.9 Prevention and control strategies of COVID-
19 
The COVID-19 is spreading worldwide so rapidly, 
while the infection rate of the virus is very high with a 
low mortality rate. The infection rate is higher than 
MERS and SARS-CoVs. Older people and peoples 




Increase in the acidic levels of endosomes, prevents the endocytosis and stops the virus 
to enter in the host cell 
Remdesivir With the help of RNA template, it prevents the RNA reproduction 
Lopinavir and 
Ritonavir 
Prevents RNA translation progression 
Ribavarin Prevents mRNA capping and synthesis of viral RNA 
Darunavir Stops the viral reproduction 
Favipiravir 
From the RNA template, it prevents the RNA reproduction and also, prevents RNA 
translation progression 
 
Oseltamivir Prevents RNA translation progression 
Arbidol Prevents the outer membrane synthesis of the viral outer surface 
Monoclonal antibodies Prevents the viral infection 
Umifenovir Prevents virions synthesis through endosomal membrane 
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with lower immunity are at higher risk of death. To 
stop this rapid spreading of the virus isolation is 
needed. Till now there is no specific medicine and 
vaccine to combat the disease. Oxygen therapy and 
symptomatic care strategies are currently used to treat. 
Vaccination of prophylactic type is compulsory for the 
upcoming slowdown of COVID linked widespread and 
epidemic. In the community, the main measure for 
interrupting the transmission of the disease is the 
isolation of the infected individuals. For example in 
China, the decision was taken by Chinese medical 
authorities to quarantine suspected individuals for 14 
days and isolated infected people [39]. Till now there 
is doubt of the virus’s origin some says it came from 
animals like a bat [73], others say it came from snakes 
[74], so it is necessary to immediately stop eating these 
animals and stop coming in close contact with these 
animal’s fluid and or tissues. People's education is also 
needed for spreading the disease and to get quick 
treatment. Individuals having symptoms like fever, 
shortness of breath, and or cough should immediately 
seek medical experts. For stopping the spread of the 
virus in large communities following things should be 
maintained like home isolation, mitigating social 
gatherings, temporary school closure, close nursing of 
symptomatic cases, wearing personal protective gears 
like a face mask, face shields, and carrying hand 
sanitizers, provision of life supports (e.g. oxygen 
supplier and mechanical ventilator), etc. In Wuhan 
city, Chinese authorities had taken lockdown 
measures seriously and strictly which stopped/slowed 
down the virus spreading [39, 75]. Ways of travel 
showed be minimized except for compulsory medical 
care. Setup of temperature scanning or checking is 
compulsory at the airport as well as at the border to 
recognize the suspected individuals. Further research 
with this COVID-19 virus is serious to find the 
outbreak source and to give proof of the upcoming 
epidemics [71]. Few vaccines are used nowadays. The 
vaccines that are administered by WHO are shown in 
Table 2 [76]. 
 
2. Indian strategy for COVID-19 
prevention and control 
The containment policies of India include 
detecting the positive cases and keeping them in 
isolation, social distancing, home quarantine, 
following additional medical guidance. Currently in 
India, 29,822,764 confirmed cases and 389,452 death 
cases have been reported, which is shown in Figure 6 
[77]. Present protocols of treatment contain analyzes 
of Point-of-Care molecular tests and also real-time 
PCR diagnosis. The person who is at higher risk of 
COVID-19 such as forefront staffs and asymptomatic 
confirmed COVID cases are given 
Hydroxychloroquine or HCQ drug (An antimalarial 
drug). The Hydroxychloroquine medicine dozes are 
given as 400 mg two times a day for one day and later 
400 mg once every week which will continue for seven 
weeks. Though, pregnant women and kids below 
fifteen years are not suitable for this drug [78]. 
The critical patients are given 
Hydroxychloroquine with Azithromycin drug. The 
dozes of Hydroxychloroquine and Azithromycin drug 
are 400 mg two times a day for one day and later 
200 mg two times a day which will continue for four 
days, and 500 mg one time a day which will continue 
for five days, respectively [79]. India introduced a 
mobile app named ‘Arogya Setu’ for tracing the 
activities of the people and also initiated plasma 
therapy to fight against the novel coronavirus. The 
government of India has initiated a complete 
lockdown and maintaining the social distance for the 
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prevention of COVID-19 [78]. The lockdown schedule 
follows Phase-I: March 25 – April 14 [85][80]; Phase-
II: April 14 – May 3; Phase-III: May 4 – May 17; and 
Phase-IV: May 18 – May 31, 2020. In this pandemic 
situation, a supplementary test has been 
recommended as a rapid antibody test which is needed 
to keep in observation as the test reports are given after 
7 to 10 days. As the laboratories are receiving a lot of 
samples for examining, pool testing is introduced in 
this placed so that the process does not take a longer 
time (five samples are examined at once). For in-vitro 
a famous drug for malaria Hydroxychloroquine 
showed hindering effect for COVID-19 for this reason 
this drug became the trial choice [81].  Although, the 
use of this drug or in combination with another 
macrolide drug already showed adverse 
cardiovascular outcomes for the QT period [81, 82]. 
Though, there is no proof that this drug is effective for 
this virus either alone or azithromycin combination, 
except there is a risk of ventricular arrhythmias has 
been shown by many researchers [83]. In India 
improving plasma therapy on various COVID-19 
infected patients is done on those who were having a 
saturation of oxygen in the bloodless than 90 % and 
rate of respiration greater than 30 breaths per minutes 
or having lungs infiltrations [84]. The selection of 
donors who were recovered after 28 days of having low 
viral load for plasma therapy are very specific i.e. they 
should be below 60 years old and should not have any 
pre-existing health conditions like hypertension, 
diabetes, and/or problems related to the heart [85, 
86].  CSIR (Council of Scientific and Industrial 
Research of India already started working on more 
advanced vaccine development like the recombinant 
DNA vaccine and RNA vaccine for the C OVID-19 
virus. The trials of ACQH are already being started by 
CSIR as it showed acceptable results in the case of the 
treatment of Dengue. This ACQH is an extraction of a 
plant which are found in areas like Madhya Pradesh, 
Jharkhand, and Gujrat Indian states [87]. 
Furthermore, Favipiravir drug clinical trial is also 
being done in India [88]. With the advancement of 
smartphone technology, India launched an App for 
both android and ios which is a useful intelligent 
software for awareness spreading of the coronavirus 
for the citizens of India [89].  This app provides various 
latest information like the total number of infected, the 
total number of the recovered, infected area, read 
zones, several peoples using this app near me within a 
radius of 50 km, 200 km as well as latest news and 
health services, etc. The software of the app uses 
smartphone Bluetooth and GPS to work properly, it 
tells the user whether he/she has come in contact with 
an infected individual or area by the database search of 
the country’s confirmed case area. The infected 
individual’s information is kept confidential because 
he/she does not face any social discrimination or 
rejection fear from the society peoples. Due to 
lockdown and different types of prevention, the new 
active cases of COVID-19 were able to control. 
Although, in the mid-week of September 2020, the 
new active COVID-19 positive cases increased it is 
observed that within mid-week February 2021, the 
new active cases decreased. Suddenly a huge number 
of new active COVID-19 cases was observed in the last 
week of March 2021 [77]. Simultaneously with 
COVID-19, a fungal infectious disease named “Black 
Fungus” was detected in the patients who recovered 
from COVID-19 [90]. 
3. Second wave of COVID-19 in India: 
Causes and effects 
Presently, India is going through a tough situation 
due to the second wave of COVID-19. As the days are 
passing by, the number of active cases is rising, and 
therefore India is going through a major medical crisis. 
There is a high demand for oxygen supplies but due to 
the medical crisis, India is unable to fulfill its oxygen 
demand. Few reasons for this deadly attack of COVID-
19 for the second time in India can’t be neglected. As 
India is a third-world developing country with a huge 
population [91], there is a lack of proper 
implementation of rules and regulations. In 2020, 
people took COVID-19 seriously and they used to wear 
 
 
Figure 6. The present situation of COVID-19 in India 
[Worldometers, 18 June, 2021] 
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masks properly but as time passed there was a lack in 
the seriousness of proper way of wearing masks and 
sanitization. These are the basic habits that will help 
the public to fight against COVID-19 [92]. In 
maximum cases, it is noticed people are wearing 
single-layer cloth masks which increases the 
possibility of getting infected [93]. People should use 
double masking, a cloth mask above a three-layer 
mask, or wearing an N95 mask to avoid getting 
infected [94]. Due to the financial condition of Indian 
common people, individuals are bound to go to their 
respective workplace, therefore they have to avail the 
public transport which leads to increase in the number 
of active cases. Frontline workers like police, health 
workers, and other social workers, are working their 
sweat out are mostly getting affected due to the direct 
contact with more public. There is no growth of 
antibodies in the previously COVID-19 affected 
patients, due to which they are getting infected for the 
second time. In rural areas people share a common 
space to live in, therefore, when an infected person 
comes in contact with the non-infected person, for 
instant, using a common bathroom, the non-infected 
person gets infected. Indian government imposes few 
rules on social activities and occasions, but 
commoners were unable to maintain it in a proper way 
(improper use of mask, lack in the use of sanitizer and 
surface disinfected, and lack in proper social 
distancing). Due to the huge population, the Indian 
government is facing a huge challenge to vaccinate 
every individual, which leads to an insufficient vaccine, 
which is increasing the active number of cases in India. 
Although the Indian government (both central and 
state) took many initiatives but also several others 
NGOs started COVID-care support. IIEST-Shibpur, 
Howrah has started a COVID- care unit in their 
campus [95], they also initiated to vaccinate their 
employees, students, and their families. 
 
4. Conclusions 
The novel coronavirus is spreading worldwide 
very rapidly. The infection from this novel coronavirus 
is much higher concerning than MERS and SARS. 
From the R0 value is found out that the infection rate 
of SARS-CoV-2 is very high. Elderly people and those 
with weakened immune systems are at higher risk of 
dying and multi-organ failure. To cut the quick spread 
of the virus, social activities should be stopped and 
home lockdown and isolation are needed. Children 
below 15 years of age get no or less infected from this 
virus. Oxygen therapy and symptomatic care are the 
current treatment strategies. Vaccination of 
prophylactic type is needed for upcoming inhibition of 
COVID-19 related pandemic and epidemic. 
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